Literature DB >> 28379384

Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3.

Katherine Wesseling-Perry1, Riikka E Mäkitie2, Ville-Valtteri Välimäki3, Tero Laine4, Christine M Laine5,6, Matti J Välimäki7, Renata C Pereira1, Outi Mäkitie2,5,8,9.   

Abstract

Context: Osteocytes express proteins that regulate bone remodeling and mineralization. Objective: To evaluate the relationship between osteocyte-specific protein expression and bone histology in patients with monogenic osteoporosis due to wingless integration site 1 (WNT1) or plastin 3 (PLS3) mutations. Design and Setting: Cross-sectional cohort study at a university hospital. Participants: Six patients (four males; ages: 14 to 72 years) with a heterozygous WNT1 mutation and five patients (four males; ages: 9 to 70 years) with a heterozygous/hemizygous PLS3 mutation. Methods and Main Outcome Measures: Immunohistochemistry was performed for fibroblast growth factor 23 (FGF23), dentin matrix protein 1 (DMP1), sclerostin, and phosphorylated (phospho-)β-catenin in iliac crest samples and compared with bone histomorphometry.
Results: FGF23 expression in WNT1 patients was 243% that observed in PLS3 patients (P < 0.01). DMP1, sclerostin, and phospho-β-catenin expression did not differ between groups. Serum phosphate correlated inversely with FGF23 expression (r = -0.79, P = 0.01) and serum ionized calcium correlated inversely with sclerostin expression (r = -0.60, P = 0.05). Phospho-β-catenin expression correlated inversely with DMP1 expression (r = -0.88, P < 0.001), osteoid volume/bone volume (r = -0.68, P = 0.02), and bone formation rate (r = -0.78, P < 0.01). FGF23 expression did not correlate with DMP1 expression, sclerostin expression, or bone histomorphometry. Marrow adiposity was higher in WNT1 than in PLS3 patients (P = 0.04). Conclusions: Mutations that disrupt WNT signaling and osteocytic mechanosensing affect osteocyte protein expression. Abnormal osteocyte function may play a role in the pathogenesis of monogenetic forms of osteoporosis.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379384      PMCID: PMC5505188          DOI: 10.1210/jc.2017-00099

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.

Authors:  Ville-Valtteri Välimäki; Outi Mäkitie; Renata Pereira; Christine Laine; Katherine Wesseling-Perry; Jorma Määttä; Mikko Kirjavainen; Heli Viljakainen; Matti J Välimäki
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

2.  Regulation of osteoblastogenesis and bone mass by Wnt10b.

Authors:  Christina N Bennett; Kenneth A Longo; Wendy S Wright; Larry J Suva; Timothy F Lane; Kurt D Hankenson; Ormond A MacDougald
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

3.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Authors:  T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

4.  Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23.

Authors:  Yinshi Ren; Xianglong Han; Yan Jing; Baozhi Yuan; Huazhu Ke; Min Liu; Jian Q Feng
Journal:  Matrix Biol       Date:  2015-12-22       Impact factor: 11.583

5.  Bone biopsy findings and correlation with clinical, radiological, and biochemical parameters in children with fractures.

Authors:  Mervi K Mäyränpää; Inari S Tamminen; Heikki Kröger; Outi Mäkitie
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

6.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.

Authors:  Aline Martin; Shiguang Liu; Valentin David; Hua Li; Anastasios Karydis; Jian Q Feng; L Darryl Quarles
Journal:  FASEB J       Date:  2011-04-20       Impact factor: 5.191

8.  Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis.

Authors:  J Justesen; K Stenderup; E N Ebbesen; L Mosekilde; T Steiniche; M Kassem
Journal:  Biogerontology       Date:  2001       Impact factor: 4.277

9.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

10.  Tetracycline double-labeling of iliac trabecular bone in 41 normal adults.

Authors:  F Melsen; L Mosekilde
Journal:  Calcif Tissue Res       Date:  1978-12-08
View more
  13 in total

Review 1.  Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society.

Authors:  Josefine Tratwal; Rossella Labella; Nathalie Bravenboer; Greet Kerckhofs; Eleni Douni; Erica L Scheller; Sammy Badr; Dimitrios C Karampinos; Sarah Beck-Cormier; Biagio Palmisano; Antonella Poloni; Maria J Moreno-Aliaga; Jackie Fretz; Matthew S Rodeheffer; Parastoo Boroumand; Clifford J Rosen; Mark C Horowitz; Bram C J van der Eerden; Annegreet G Veldhuis-Vlug; Olaia Naveiras
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-28       Impact factor: 5.555

Review 2.  Plastin 3 in health and disease: a matter of balance.

Authors:  Lisa Wolff; Eike A Strathmann; Ilka Müller; Daniela Mählich; Charlotte Veltman; Anja Niehoff; Brunhilde Wirth
Journal:  Cell Mol Life Sci       Date:  2021-05-23       Impact factor: 9.261

3.  A Clinical Perspective on Advanced Developments in Bone Biopsy Assessment in Rare Bone Disorders.

Authors:  Sanne Treurniet; Elisabeth M W Eekhoff; Felix N Schmidt; Dimitra Micha; Björn Busse; Nathalie Bravenboer
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-23       Impact factor: 5.555

Review 4.  New Insights Into Monogenic Causes of Osteoporosis.

Authors:  Riikka E Mäkitie; Alice Costantini; Anders Kämpe; Jessica J Alm; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-25       Impact factor: 5.555

5.  MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections.

Authors:  Josefine Tratwal; David Bekri; Chiheb Boussema; Rita Sarkis; Nicolas Kunz; Tereza Koliqi; Shanti Rojas-Sutterlin; Frédérica Schyrr; Daniel Naveed Tavakol; Vasco Campos; Erica L Scheller; Rossella Sarro; Carmen Bárcena; Bettina Bisig; Valentina Nardi; Laurence de Leval; Olivier Burri; Olaia Naveiras
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-24       Impact factor: 5.555

6.  A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta.

Authors:  Jing Hu; Lu-Jiao Li; Wen-Bin Zheng; Di-Chen Zhao; Ou Wang; Yan Jiang; Xiao-Ping Xing; Mei Li; Weibo Xia
Journal:  Mol Genet Genomic Med       Date:  2020-11-09       Impact factor: 2.183

7.  PLS3 Mutations Cause Severe Age and Sex-Related Spinal Pathology.

Authors:  Riikka E Mäkitie; Tuukka Niinimäki; Maria Suo-Palosaari; Anders Kämpe; Alice Costantini; Sanna Toiviainen-Salo; Jaakko Niinimäki; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-23       Impact factor: 5.555

Review 8.  The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.

Authors:  Janak L Pathak; Nathalie Bravenboer; Jenneke Klein-Nulend
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-08       Impact factor: 5.555

Review 9.  Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.

Authors:  Hanh H Nguyen; Denise M van de Laarschot; Annemieke JMH Verkerk; Frances Milat; M Carola Zillikens; Peter R Ebeling
Journal:  JBMR Plus       Date:  2018-01-03

Review 10.  The Polygenic and Monogenic Basis of Paediatric Fractures.

Authors:  S Ghatan; A Costantini; R Li; C De Bruin; N M Appelman-Dijkstra; E M Winter; L Oei; Carolina Medina-Gomez
Journal:  Curr Osteoporos Rep       Date:  2021-05-04       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.